Nomura Risa, Suzuki Shota, Nishikawa Koki, Suzuki Hiroshi, Fujiyoshi Yoshinori
Cellular and Structural Physiology Laboratory (CeSPL), Advanced Research Initiative, Institute of Science Tokyo, 1-5-45 Yushima Bunkyo-ku, Tokyo 113-8510, Japan.
Joint Research Course for Advanced Biomolecular Characterization, Tokyo University of Agriculture and Technology, Tokyo 183-8538, Japan.
J Struct Biol. 2025 Sep;217(3):108223. doi: 10.1016/j.jsb.2025.108223. Epub 2025 Jun 2.
Adenylyl cyclase 9 (AC9) regulates many physiologic functions through the production of cAMP, an important second messenger that regulates downstream effectors. The activation of AC9 is highly regulated by GPCR signaling. For example, AC9 is activated by the binding of Gαs, which, in turn, is activated by Gs-driven GPCRs. The structure of bovine AC9 (bAC9) was reported in 2019 using single-particle cryo-electron microscopy (cryo-EM). The structure of human AC9 (hAC9), however, has not been reported to date despite its potential benefit for drug development. Here, we analyzed the structures of hAC9 and hAC9 in complex with Gαs (hAC9-Gαs) using single-particle cryo-EM. The soluble domain of AC9-Gαs, the transmembrane (TM) domain of AC9-Gαs, and AC9 alone were analyzed at resolutions of 2.7 Å, 3.4 Å, and 3.2 Å, respectively. The results revealed three key aspects of the activation mechanism of hAC9 and its cAMP-generating function. First, a conformational change of the soluble domain was observed upon Gαs binding, resulting in a widely open catalytic site. Second, we analyzed the exact position of the C-terminus occluding the catalytic site in the hAC9-Gαs complex. Finally, we unexpectedly identified an elongated density suggestive of a single acyl chain in the TM domain. Consistent with recent reports on the allosteric regulation of AC by lipids, this finding suggests that the TM domain could serve as a potential drug target.These structural findings enhance our understanding of the structure and function of AC9 and other ACs and will provide a foundation for future AC-target drug discovery.
腺苷酸环化酶9(AC9)通过产生环磷酸腺苷(cAMP)来调节多种生理功能,cAMP是一种重要的第二信使,可调节下游效应器。AC9的激活受到G蛋白偶联受体(GPCR)信号通路的高度调控。例如,AC9通过Gαs的结合而被激活,而Gαs又由Gs驱动的GPCR激活。2019年利用单颗粒冷冻电子显微镜(cryo-EM)报道了牛AC9(bAC9)的结构。然而,尽管人AC9(hAC9)对药物开发具有潜在益处,但迄今为止其结构尚未见报道。在此,我们利用单颗粒冷冻电子显微镜分析了hAC9以及与Gαs结合的hAC9(hAC9-Gαs)的结构。分别以2.7 Å、3.4 Å和3.2 Å的分辨率分析了AC9-Gαs的可溶性结构域、AC9-Gαs的跨膜(TM)结构域以及单独的AC9。结果揭示了hAC9激活机制及其cAMP生成功能的三个关键方面。首先,观察到Gαs结合后可溶性结构域发生构象变化,导致催化位点广泛开放。其次,我们分析了hAC9-Gαs复合物中封闭催化位点的C末端的确切位置。最后,我们意外地在TM结构域中发现了一条暗示单酰基链的细长密度。与最近关于脂质对AC变构调节的报道一致,这一发现表明TM结构域可能是一个潜在的药物靶点。这些结构发现加深了我们对AC9和其他腺苷酸环化酶结构与功能的理解,并将为未来基于AC靶点的药物发现奠定基础。